InsiderSignal.AI

InsiderSignal.ai

EYPT - Eyepoint, Inc.

Insider Sale by Ribeiro Ramiro (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Ribeiro Ramiro, serving as Chief Medical Officer at Eyepoint, Inc. (EYPT), sold 2,438 shares at $17.87 per share, for a total transaction value of $43,572.00.

This sale represents a 100.00% decrease in Ribeiro Ramiro's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, March 4, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 5, 2026, 1 day after the trade was made.

Eyepoint, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ribeiro Ramiro

Chief Medical Officer

Ramiro Ribeiro, M.D., Ph.D., is the Chief Medical Officer at EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), appointed on March 1, 2024, succeeding Dario Paggiarino.[[1]](https://fintool.com/app/research/companies/EYPT/people/ramiro-ribeiro)[[2]](https://www.thepharmaletter.com/pharmaceutical/eyepoint-pharmaceuticals-appoints-new-cmo)[[5]](https://www.biocentury.com/article/651639/eyepoint-names-ribeiro-cmo)[[6]](https://www.biospace.com/eyepoint-pharmaceuticals-announces-appointment-of-ramiro-ribeiro-m-d-ph-d-as-chief-medical-officer) A 42-year-old trained retinal specialist, he previously served as Vice President and Head of Clinical Development in Ophthalmology at Apellis Pharmaceuticals from 2018 to March 2024, where he led the global Phase 3 geographic atrophy program resulting in the NDA submission and FDA approval of SYFOVRE.[[1]](https://fintool.com/app/research/companies/EYPT/people/ramiro-ribeiro) His earlier career includes leadership roles at Acucela, Ophthotech (Iveric Bio), Alcon, Replenish, and 1Co.[[1]](https://fintool.com/app/research/companies/EYPT/people/ramiro-ribeiro) Ribeiro holds an M.D. from Pontifical Catholic University and a Ph.D. in stem cell therapy for retinal degenerative diseases from Federal University of São Paulo, and completed a research fellowship at the University of Southern California (USC).[[1]](https://fintool.com/app/research/companies/EYPT/people/ramiro-ribeiro) At EyePoint, he has contributed to advancing the company's sustained drug delivery pipeline, including articulating Phase 2 VERONA data for DURAVYU in diabetic macular edema (DME) and overseeing Phase 3 trials for wet AMD and DME.[[1]](https://fintool.com/app/research/companies/EYPT/people/ramiro-ribeiro)[[4]](https://www.youtube.com/watch?v=uUQQfh-Qeng)

View full insider profile →

Trade Price

$17.87

Quantity

2,438

Total Value

$43,572.00

Shares Owned

0

Trade Date

Wednesday, March 4, 2026

2 days ago

SEC Filing Date

Thursday, March 5, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Eyepoint, Inc.

Company Overview

No company information available
View news mentioning EYPT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4523965

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime